Unresectable hepatocellular carcinoma (HCC) is an advanced primary liver malignancy with a poor prognosis. The Food and Drug Administration (FDA) has, to date, approved nivolumab, pembrolizumab, ramucirumab, nivolumab/ipilimumab, atezolizumab/bevacizumab, as well as tremelimumab/durvalumab, as first- or second-line monoclonal antibodies (mAbs) for unresectable HCC. The present review examines the current state of knowledge, and provides a useful update on the safety and efficacy of these therapeutic agents, thus attempting to define the suitability of each mAb for different patient subgroups.
CITATION STYLE
Psilopatis, I., Damaskos, C., Garmpi, A., Sarantis, P., Koustas, E., Antoniou, E. A., … Garmpis, N. (2023, February 1). FDA-Approved Monoclonal Antibodies for Unresectable Hepatocellular Carcinoma: What Do We Know So Far? International Journal of Molecular Sciences. MDPI. https://doi.org/10.3390/ijms24032685
Mendeley helps you to discover research relevant for your work.